Kolosis BIO

Executive Summary

Kolosis BIO is a global pure-play biologics company headquartered in Salt Lake City, Utah, focused exclusively on commercializing allograft technologies sourced from MTF Biologics. Established in 2020, the company provides advanced orthobiologic solutions, including bone grafts and extracellular matrices, for surgical applications in spine, orthopedics, and wound care. Kolosis BIO's mission is to deliver best-in-class technologies through a partnership-driven, execution-focused commercial model. Operating in the United States, the company targets the growing biologics market with a strategy centered on leveraging established allograft products. Despite its pre-clinical classification, the company appears to be commercializing existing technologies, which may indicate a revenue-generating stage. The company's profile is sparse, with no disclosed funding, valuation, or pipeline data, making it a high-risk opportunity with limited visibility. However, its association with MTF Biologics provides a foundation for credible product offerings in orthobiologics.

Upcoming Catalysts (preview)

• Q2 2026New Allograft Product Launch60% success
• Q3 2026Strategic Partnership Announcement50% success
• Q4 2026FDA 510(k) Clearance for Novel Orthobiologic Device40% success